Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14258949 | 0.90 | KMT2A (0.41) | RAB9ASMN1; SMN2NPC1HTTP2RY1 | |
| SCHEMBL14257651 | 0.90 | KMT2A (0.41) | RAB9ASMN1; SMN2NPC1HTTP2RY1 | |
| SCHEMBL14267805 | 0.87 | SMN1; SMN2 (0.35) | RAB9ASMN1; SMN2NPC1HTTP2RY1 | |
| SCHEMBL14257526 | 0.87 | KMT2A (0.43) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL14257481 | 0.87 | LMNA (0.39) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL14257580 | 0.86 | NPC1 (0.46) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL14257606 | 0.84 | KMT2A (0.37) | RAB9ASMN1; SMN2NPC1P2RY1ALDH1A1 | |
| SCHEMBL14257545 | 0.81 | FAAH (0.41) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL4500748 | 0.81 | FAAH (0.41) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL4500750 | 0.81 | FAAH (0.41) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | RAB9A 3303/4885SMN1; SMN2 3822/4885NPC1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.